Page last updated: 2024-11-06

nivimedone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nivimedone: inhibits mediator release & capillary permeability; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64753
CHEMBL ID3230480
SCHEMBL ID1813861
MeSH IDM0058984

Synonyms (16)

Synonym
nivimedone
nivimedonum [inn-latin]
5,6-dimethyl-2-nitroindene-1,3-dione
1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-
49561-92-4
unii-1m887244yi
nivimedona [inn-spanish]
nivimedona
nivimedonum
nivimedone [inn:ban]
5,6-dimethyl-2-nitro-1h-indene-1,3(2h)-dione
CHEMBL3230480
5,6-dimethyl-2-nitro-indane-1,3-dione
KMQFWCXRCDQFFQ-UHFFFAOYSA-N
SCHEMBL1813861
DTXSID80197841
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1123016Antiallergic activity in po dosed human assessed as oral active dose1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1123015Antiallergic activity in po dosed Wistar rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis relative to DSCG1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
AID1123014Antiallergic activity in po dosed Wistar rat assessed as inhibition of ovalbumin-induced passive cutaneous anaphylaxis1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Development of ethyl 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylate, a new prototype with oral antiallergy activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]